Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and non-pregnant female patients 16-70 years of age (inclusive)~* Confirmed diagnosis of sickle cell disease by hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) \[performed locally\]. All sickle cell disease genotypes are eligible.~* Experienced at least 1 VOC within the preceding 12 months prior to Screening, as determined by medical history.~* If receiving HU/HC or erythropoietin stimulating agent, must have been receiving the drug for at least 6 months prior to Screening~* Hemoglobin ≥4.0 g/dL. Absolute neutrophil count ≥1.0 x 109/L and platelet count ≥75 x 109/L~* Adequate renal and hepatic function as defined:~* GFR ≥45 mL/min/1.73 m2 calculated by CKD-EPI~* ALT ≤3 x ULN~* Direct (conjugated) bilirubin ≤2 x ULN~* ECOG performance status ≤2~* Written informed consent (or assent/ parental consent for minor subjects) prior to any screening procedures~Exclusion Criteria:~* History of stem cell transplant.~* Acute VOC ending 7 days prior to first dosing~* Ongoing hospitalization prior to Screening~* Received blood products within 30 days to first dosing~* Participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes)~* History of severe hypersensitivity reactions to other monoclonal antibodies~* Received a monoclonal antibody or immunoglobulin -based agent within 1 year of Screening, or has documented immunogenicity to a prior biologic.~* Received active treatment on another investigational trial within 30 days (or 5 half-lives of that agent, whichever is greater) prior to Screening~* Significant active infection or immune deficiency (including chronic use of immunosuppressive drugs)~* Resting QTcF ≥470 msec at pretreatment (baseline) or other cardiac or cardiac repolarization abnormality

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- crizanlizumab (Type: EXPERIMENTAL): SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).